Cargando…

TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer

BACKGROUND: Breast cancer (BC) is the most frequent female cancer and preferentially metastasizes to bone. The transcription factor TGFB-induced factor homeobox 1 (TGIF) is involved in bone metabolism. However, it is not yet known whether TGIF is associated with BC bone metastasis or patient outcome...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stürken, Christine, Möbus, Volker, Milde-Langosch, Karin, Schmatloch, Sabine, Fasching, Peter A., Rüschoff, Josef, Stickeler, Elmar, Henke, Rolf-Peter, Denkert, Carsten, Hanker, Lars, Schem, Christian, Vladimirova, Valentina, Karn, Thomas, Nekljudova, Valentina, Köhne, Claus-Henning, Marmé, Frederik, Schumacher, Udo, Loibl, Sibylle, Müller, Volkmar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8364691/ https://www.ncbi.nlm.nih.gov/pubmed/34391399 http://dx.doi.org/10.1186/s12885-021-08656-0

Ejemplares similares

Correction to: TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer
por: Stürken, Christine, et al.
Publicado: (2021)

Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial
por: Fasching, Peter A., et al.
Publicado: (2023)

Cardiotoxicity and Cardiovascular Biomarkers in Patients With Breast Cancer: Data From the GeparOcto‐GBG 84 Trial
por: Rüger, Alexandra Maria, et al.
Publicado: (2020)

Characterization of Hormone Receptor and HER2 Status in Breast Cancer Using Mass Spectrometry Imaging
por: Gonçalves, Juliana Pereira Lopes, et al.
Publicado: (2023)

Clinical Relevance of Collagen Protein Degradation Markers C3M and C4M in the Serum of Breast Cancer Patients Treated with Neoadjuvant Therapy in the GeparQuinto Trial
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2019)

EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy
por: Leichsenring, Jonas, et al.
Publicado: (2022)

Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial
por: Witzel, Isabell, et al.
Publicado: (2019)

MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial
por: Jank, Paul, et al.
Publicado: (2020)

Correction: MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial
por: Jank, Paul, et al.
Publicado: (2021)

Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial
por: Stevic, Ines, et al.
Publicado: (2018)

DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status
por: Jurmeister, Philipp, et al.
Publicado: (2021)

Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC
por: Massa, Chiara, et al.
Publicado: (2020)

The homeobox gene TGIF1 is required for chicken ovarian cortical development and generation of the juxtacortical medulla
por: Estermann, Martin Andres, et al.
Publicado: (2021)

Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy
por: Sinn, Bruno Valentin, et al.
Publicado: (2019)

Predicting Prognosis of Breast Cancer Patients with Brain Metastases in the BMBC Registry—Comparison of Three Different GPA Prognostic Scores
por: Riecke, Kerstin, et al.
Publicado: (2021)

Characteristics and Clinical Outcome of Breast Cancer Patients with Asymptomatic Brain Metastases
por: Laakmann, Elena, et al.
Publicado: (2020)

Tgif1 and Tgif2 Regulate Axial Patterning in Mouse
por: Melhuish, Tiffany A., et al.
Publicado: (2016)

Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: Pharmacokinetic, safety and patients' preference - Substudy of the randomised phase III GAIN-2 study
por: Reinisch, Mattea, et al.
Publicado: (2022)

The role of the desmosomal protein desmocollin 2 in tumour progression in triple negative breast cancer patients
por: Reimer, Francesca, et al.
Publicado: (2023)

BmTGIF, a Bombyx mori Homolog of Drosophila DmTGIF, Regulates Progression of Spermatogenesis
por: Zhang, Pengjie, et al.
Publicado: (2012)

Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab – a translational project in the neoadjuvant GeparQuinto trial
por: Witzel, I, et al.
Publicado: (2012)

Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto
por: Laakmann, Elena, et al.
Publicado: (2019)

Role of urokinase plasminogen activator and plasminogen activator inhibitor mRNA expression as prognostic factors in molecular subtypes of breast cancer
por: Witzel, Isabell, et al.
Publicado: (2014)

Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial
por: Gerber, Bernd, et al.
Publicado: (2022)

Differential roles of TGIF family genes in mammalian reproduction
por: Hu, Yanqiu, et al.
Publicado: (2011)

TGIF-DB: terse genomics interface for developing botany
por: Tsugama, Daisuke, et al.
Publicado: (2021)

Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer
por: Meng, Xiaodan, et al.
Publicado: (2016)

AGO Algorithms for the Treatment of Breast Cancer: Update 2021
por: Schneeweiss, Andreas, et al.
Publicado: (2021)

TGIF1-Twist1 axis in pancreatic ductal adenocarcinoma
por: Razzaque, Mohammed S., et al.
Publicado: (2020)

Metabolomics of human breast cancer: new approaches for tumor typing and biomarker discovery
por: Denkert, Carsten, et al.
Publicado: (2012)

Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy
por: Darb-Esfahani, Silvia, et al.
Publicado: (2016)

Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients
por: Eichelser, Corinna, et al.
Publicado: (2014)

Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy
por: Huober, Jens, et al.
Publicado: (2023)

Loss of Tgif Function Causes Holoprosencephaly by Disrupting the Shh Signaling Pathway
por: Taniguchi, Kenichiro, et al.
Publicado: (2012)

Premature Senescence and Increased TGFβ Signaling in the Absence of Tgif1
por: Zerlanko, Brad J., et al.
Publicado: (2012)

The TFEB-TGIF1 axis regulates EMT in mouse epicardial cells
por: Astanina, Elena, et al.
Publicado: (2022)

TGIF1 overexpression promotes glioma progression and worsens patient prognosis
por: Wang, Baoya, et al.
Publicado: (2022)

Fra-2 overexpression upregulates pro-metastatic cell-adhesion molecules, promotes pulmonary metastasis, and reduces survival in a spontaneous xenograft model of human breast cancer
por: Arnold, Sabrina, et al.
Publicado: (2021)

Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis
por: Loibl, Sibylle, et al.
Publicado: (2011)

Production and purification of TGFb-1 in CHO-Cells
por: Abdulkerim, Estabraq, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_8fplsdnl7nshgpjd7e82r2soja